

RESEARCH REPORT ON

DR.REDDY'S

LABORATORIES LIMITED



Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. The Company's segments include Global Generics, which is engaged in manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics); Pharmaceutical Services and Active Ingredients (PSAI), which is engaged in manufacturing and marketing active pharmaceutical ingredients and intermediates for finished pharmaceutical products; Proprietary Products, which focuses on research and development of differentiated formulations and Others, which consists of the Company's wholly-owned subsidiary, Aurigene Discovery Technologies Limited, which is a discovery stage biotechnology company developing novel and therapies in the fields of oncology and inflammation.

COMPANY PROFILE

Dr. Reddy's Laboratories Ltd



Type	Public
Traded as	NSE: DRREDDY BSE: 500124 NYSE: RDY NSE NIFTY 50 Constituent
ISIN	INE089A01023
Industry	Pharmaceuticals
Founded	1984 (39 years ago)
Founders	Anji Reddy
Headquarters	Hyderabad; Telangana, India
Area served	Worldwide
Key people	G. V. Prasad (Co-Chairman & MD) Kallam Satish Reddy (Chairman) Erez Israeli (CEO)

Products	Pharmaceuticals, generic drugs, over-the-counter drugs, vaccines, diagnostics, Biologics
Revenue	▲ ₹17,460 crore (US\$2.2 billion) (2020)
Operating income	▲ ₹1,599 crore (US\$200 million) (2020)
Net income	▲ ₹1,950 crore (US\$240 million) (2020)
Total assets	▲ ₹23,156 crore (US\$2.9 billion) (2020)
Total equity	▲ ₹15,499 crore (US\$1.9 billion) (2020)
Number of employees	21,650 (March 2020)
Website	www.drreddys.com

➤ FUNDAMENTALS

Market Cap ₹81,725Cr

P/E Ratio(TTM) 22.45

P/B Ratio 4.25

Industry P/E 25.47

Debt to Equity 0.08

ROE 11.82%


EPS(TTM) 219.04

Dividend Yield 0.61%

Book Value 1251.38


Face Value 5

➤ SHAREHOLDING




FINANCIALS


➤ **REVENUE**




➤ **NET PROFIT**




➤ EPS




➤ BVPS



➤ **ROE**



➤ **DEBT TO EQUITY**



TECHNICAL ANALYSIS



**BUY DRREDDY AT 4800 TARGET 5310, 5700
STOPLOSS 4295
(1-4 MONTHS)**

Community Sentiments



- 100% BUY
- 0% SELL
- 0% HOLD

100% of moneycontrol
users recommend
buying Dr Reddys
Labs

RATIO ANALYSIS

ANNUAL	FY 2022	FY 2021	FY 2020
Return on Equity (%)	8.85	12.87	19.33
Return on Capital Employed (%)	12.25	18.17	18.46
Return on Assets (%)	6.62	10.10	15.08
Interest Coverage Ratio (x)	80.95	84.32	59.07
Asset Turnover Ratio (x)	0.62	0.65	60.84
Price to Earnings (x)	44.25	34.48	17.64
Price to Book (x)	3.91	4.42	3.41
EV/EBITDA (x)	23.34	18.96	14.62
EBITDA Margin (%)	21.35	29.49	30.48

Disclaimer: This research report is prepared by Shyam Advisory Limited, while making this report we have taken data from available sources and there may be errors in the data shown. We do not guarantee the accuracy of data and recommendation given in this report. Recommendation is for information purpose only.

"Investment in Securities market are subject to market risks. Read all the related documents carefully before investing."